Market revenue in 2023 | USD 16,868.8 million |
Market revenue in 2030 | USD 16,715.2 million |
Growth rate | -0.1% (CAGR from 2023 to 2030) |
Largest segment | Clinical chemistry |
Fastest growing segment | Medical Microbiology & Cytology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Other Esoteric Tests |
Key market players worldwide | Labcorp Holdings Inc, Qiagen NV, Eurofins Scientific SE, Quest Diagnostics Inc, OPKO Health Inc, Siemens Healthineers AG ADR, NeoGenomics Inc, Fresenius Medical Care AG, Sonic Healthcare Ltd, Charles River Laboratories International Inc, SYNLAB Group, Mayo Clinic |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical laboratory service market will help companies and investors design strategic landscapes.
Clinical chemistry was the largest segment with a revenue share of 80.14% in 2023. Horizon Databook has segmented the China clinical laboratory service market based on human & tumor genetics, clinical chemistry, medical microbiology & cytology, other esoteric tests covering the revenue growth of each sub-segment from 2018 to 2030.
Some of the key factors responsible for the market growth in China are the rapidly aging population, increasing ease of accreditation of laboratories, a growing number of laboratories, and improving medical infrastructure
According to NCBI, one in ten individuals living in China meets the criteria for obesity. The high prevalence of obesity has led to a rise in the prevalence of chronic conditions, such as stroke, diabetes, and atrial fibrillation.
The increasing prevalence of chronic diseases in this country and the presence of the target population, along with high unmet clinical needs, are expected to support the market growth. Most of the companies in this country have a domestic supply of tests and services due to regulatory restrictions. Most Chinese CROs are wholly owned and are self-sufficient in conducting trials.
Horizon Databook provides a detailed overview of country-level data and insights on the China clinical laboratory service market , including forecasts for subscribers. This country databook contains high-level insights into China clinical laboratory service market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account